Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate.
Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection.
Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins Clinically Discordant for Multiple Sclerosis.
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Effects of dimethyl fumarate on lymphocyte subsets.
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis
Transdermal Application of Myelin Peptides in Multiple Sclerosis Treatment.
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects.
Primary Progressive MS evolving from Radiologically Isolated Syndrome.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Our Products (page shows "Copaxone" as a trade name for glatiramer acetate)
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
Peripheral Bilateral Telangiectasiae in Multiple Sclerosis Patients Treated with Interferon B1a.
Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus - induced demyelinating disease by modifying Nrf2-Keap1 pathway.
Synaptic pathology: a shared mechanism in neurological disease.
Flupirtine
Imaging in Pediatric Demyelinating and Inflammatory Diseases of Brain- Part 2.
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Effects of fumaric acid esters on blood-brain barrier tight junction proteins.
More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Berlex continues legal challenge to FDA over MS drug.

Pages